AtriCure to Present at the Needham & Company’s 17th Annual Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Needham & Company’s 17th Annual Healthcare Conference at the Westin Grand Central in New York on Tuesday, March 27, 2018. Management is scheduled to present at 1:30 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 125,000 implanted to date. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180315005067/en/

AtriCure, Inc.Andy Wade, 513-755-4564Senior Vice President and Chief Financial Officerawade@atricure.comorGilmartin GroupLynn Pieper Lewis, 415-937-5402Investor Relationslynn@gilmartinir.com

AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Mar 2024 to Apr 2024